Establishment Labs Holdings (Establishment Labs Holdings) Cash-to-Debt : 0.21 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Establishment Labs Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Establishment Labs Holdings's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.21.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Establishment Labs Holdings couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Establishment Labs Holdings's Cash-to-Debt or its related term are showing as below:

ESTA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 0.61 Max: 2.32
Current: 0.21

During the past 8 years, Establishment Labs Holdings's highest Cash to Debt Ratio was 2.32. The lowest was 0.01. And the median was 0.61.

ESTA's Cash-to-Debt is ranked worse than
86.31% of 862 companies
in the Medical Devices & Instruments industry
Industry Median: 2.03 vs ESTA: 0.21

Establishment Labs Holdings Cash-to-Debt Historical Data

The historical data trend for Establishment Labs Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Establishment Labs Holdings Cash-to-Debt Chart

Establishment Labs Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.78

1.61

0.99

0.37

0.21

Establishment Labs Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															0.37	0.23	0.49	0.28	0.21

Competitive Comparison of Establishment Labs Holdings's Cash-to-Debt

For the Medical Devices subindustry, Establishment Labs Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Establishment Labs Holdings's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Establishment Labs Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Establishment Labs Holdings's Cash-to-Debt falls into.

Establishment Labs Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Establishment Labs Holdings's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	40.035	/	(0.773	+	191.451)
	=	0.21

Establishment Labs Holdings's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	40.035	/	(0.773	+	191.451)
	=	0.21

Establishment Labs Holdings (NAS:ESTA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Establishment Labs Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Establishment Labs Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Establishment Labs Holdings (Establishment Labs Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Establishment Labs Holdings Inc (NAS:ESTA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

3E0:Germany

Address

Coyol Free Zone, Building B15 and 25, Alajuela, CRI

Website

https://establishmentlabs.com

Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in designing, manufacturing, and marketing silicone-filled breast and body shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.

Executives

Nicholas Sheridan Lewin	director, 10 percent owner	3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Raj Denhoy	officer: Chief Financial Officer	C/O MOTIVA USA, LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Dennis E Condon	director	811 ALSTON RD, SANTA BARBARA CA 93108
Leslie Gillin	director	C/O MOTIVA USA, LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Paul D. Rodio	officer: Chief Operating Officer	C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Samuel Ross Mansbach	other: GC & Chief Compliance Officer	C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Jw Asset Management, Llc	10 percent owner, other: See Footnote(1)	1051 N VENETIAN DRIVE, MIAMI BEACH FL 33139
Bryan Slotkin	director	C/O MOTIVA USA,.LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Ann Custin	director	C/O MOTIVA USA, LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Edward J Schutter	director	C/O FIRST HORIZON PHARMACEUTICAL CORP, 6195 SHILOH ROAD, ALPHARETTA GA 30005
Lisa Gersh	director	C/O HASBRO, INC., 1011 NEWPORT AVENUE, PAWTUCKET RI 02861
Mezerville Roberto De	officer: Chief Technology Officer	C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Renee Gaeta	officer: Chief Financial Officer	C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Pratip Dastidar	officer: Head of Global Operations	150 PEABODY PLACE, MEMPHIS TN 38103
Santos Salvador Dada	officer: Chief Operating Officer	C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958